2019 American Transplant Congress
Renal Safety Of Entecavir And Tenofovir With Hepatitis B Immunoglobulin In Liver Transplant Patients
*Purpose: Combination of potent nucleos(t)ide analougues (NAs) and hepatitis B immunoglobulin is recommended after liver transplantation for the prevention of hepatitis B virus (HBV) recurrence.…2019 American Transplant Congress
Analysis Of Public Health Service Increased Risk Donors Shows No Viral Transmission In Liver Transplant Recipients And Similar Graft / Patient Survival When Compared To Non-increased Risk Donors
Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA
*Purpose: Public Health Service increased risk donors (PHS-IRD) are underutilized in liver transplant (LT) due to concern for transmission of viral (HBV, HCV, and HIV)…2019 American Transplant Congress
De Novo Hepatitis B Virus Infection after Pediatric Living Donor Liver Transplantation: Risk Factors, Recognition and Prevention Strategies
Renji Hospital, Shanghai, China
*Purpose: To evaluate the risk factors of De novo Hepatitis B, especially the Hepatitis B serotype of both doners and recipients in pediatric living donor…2019 American Transplant Congress
Characterization Of Increased Risk Donor Post-transplant Viral Surveillance Protocol At A Comprehensive Transplant Center
University of Virginia Health System, Charlottesville, VA
*Purpose: With the growing opioid crisis, the number of deceased donors classified as Increased Risk Donor (IRD) has increased to nearly 20% nationally. The Organ…2019 American Transplant Congress
Clinical Presentation After Hepatitis B Recurrence In Liver Transplant Patients
Chang-Gung Hospital, Taoyuan, Taiwan
*Purpose: Combination of anti-hepatitis B immunoglobulin and antiviral agents is the standard care for prophylaxis of hepatitis B virus (HBV) recurrence after liver transplantation. However,…2018 American Transplant Congress
Kidney Transplantation Alone in End-Stage Renal Disease Patients with Hepatitis B Liver Cirrhosis
BackgroundKidney transplantation (KT) alone in end-stage renal disease (ESRD) patients with hepatitis B virus-induced liver cirrhosis (LC) remains controversial. This study compared outcomes of KT…2018 American Transplant Congress
Donor-Derived Hepatitis B Virus (HBV) Infection: Analysis of the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC)
DTAC, United Network for Organ Sharing, Richmond, VA.
Introduction: HBV can be transmitted from organ donor to recipient and is one of the viruses targeted by US Public Health Service increased risk (IR)…2018 American Transplant Congress
Evaluation of Hepatitis B Vaccination in Transplant Candidates
Background:Hepatitis B virus (HBV) vaccine series is recommended for all organ transplant candidates; high doses of vaccine are generally given to those with renal disease;…2018 American Transplant Congress
Renal and Bone Safety in Post Liver Transplant Patients with Chronic Kidney Disease Receiving Tenofovir Alafenamide for HBV Prophylaxis
1Auckland City Hospital, Auckland, New Zealand; 2Gilead Sciences, Foster City, CA.
Background and Aims: Chronic Hepatitis B (CHB) remains a leading indication for orthotopic liver transplantation (OLT) globally. Common complications following OLT include renal dysfunction secondary…2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
American Transplant Congress abstracts